Skip to main content
SpringerLink
Log in
Book cover

PET Scan in Hodgkin Lymphoma pp 117–136Cite as

PET Scan Reporting in Clinical Practice

  • Chapter
  • First Online:

  • 816 Accesses

Abstract

The medical report is “a written document by which the specialist states conform to the truth the results of diagnostic imaging, together with the clinical interpretation of the results themselves, in relation to the clinical and medical history” [1]. The medical report is a structured as a formal vehicle for a written and understandable communication between the doctors and eventually between the doctors and the legal system. It represents the subjective interpretation of physical findings in images by the specialist (either nuclear medicine physician or radiologist), is based on the semiotics of a given imaging technique, and provides the answer to the clinical questions arisen by the treating physician. The content of each report will vary according to the exact circumstances concerning each case. While a degree of flexibility is necessary to encompass all the relevant points, a structured framework for the reporting document is strongly recommended. In general, the PET/CT report (a) describes the presence or absence of abnormal FDG accumulation in the PET images in combination with their size and intensity, (b) correlates these findings to other diagnostic tests and interprets them in that context, and (c) contextualizes imaging findings in the available clinical information in order to reply to specific question posed by the clinician.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

5-PS:

Five-Point Scale

AIMN:

Associazione Italiana di Medicina Nucleare

BM:

Bone Marrow

CT:

Computed Tomography

DLBCL:

Diffuse Large B-Cell Lymphoma

EANM:

European Association of Nuclear Medicine

FDG:

18F-Fluoro-Deoxyglucose

HL:

Hodgkin Lymphoma

HRS:

Hodgkin and Reed-Sternberg Cells

PET:

Positron Emission Tomography

SNM:

Society of Nuclear Medicine

SUV:

Standardized Uptake Value

References

  1. Linee Guida per la Dematerializzazione della Documentazione Clinica in Diagnostica per Immagini, 4/4/2012, Conferenza permanente per i rapporti tra lo Stato, le Regioni e le provincie autonome di Trento e di Bolzano. www.statoregioni.it/dettaglio Doc.asp?idprov=10549&iddoc.

  2. Boellard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200. doi:10.1007/s00259-009-1297-4.

    Article  Google Scholar 

  3. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guidelines for tumour PET imaging with 18F-FDG PET/CT 1.0*. J Nucl Med. 2006;47:885–95.

    PubMed  Google Scholar 

  4. Giordano A, Fanti S. Raccomandazioni Procedurali AIMN – Imaging Oncologico con 18F-FDG/PET – Vrs. 03/2012. www.aimn.it/pubblicazioni/LG/RP_AIMN_18F-oncologia.pdf.

  5. 5th International workshop on PET in lymphoma. Palais de l’Europe. Menton, 19–20 Sept 2014. Organizing Committee M. Meignan, A. Gallamini, C. Haioun, S. Barrington, E. Itti, S. Luminari, E. Zucca. www.lymphomapet.com.

  6. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on Malignant Lymphomas Imaging Working Group. doi:10.1200/JCO.2013.53.5229.

    Google Scholar 

  7. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. doi:10.1200/JCO.2013.54.8800.

    Google Scholar 

  8. Cheson BD, Pfstner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.

    Article  PubMed  Google Scholar 

  9. Biggi A, Guerra L, Hofman MS. Current status of FDG-PET/CT in staging of adults lymphoma. Clin Transl Imaging. 2015. doi:10.1007/s40336-015-0127-x.

    Google Scholar 

  10. Rosemberg SA, Dorfman RF, Kaplan HS. The value of sequential bone marrow biopsy and laparotomy and splenectomy in a series of 127 consecutive untreated patients. Br J Cancer Suppl. 1975;2:221–7.

    Google Scholar 

  11. Khan AB, Barrington S, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013;122:61–7. doi:10.1182/blood2012-12-473389.

    Article  CAS  PubMed  Google Scholar 

  12. Adams HJA, Kwee TC, Fijnheer R, et al. Bone marrow 18-F-fluoro-2-deoxy-Dglucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol. 2014;89:726–31.

    Article  CAS  PubMed  Google Scholar 

  13. Adams HJ, de Klerk JM, Fijnheer R, et al. Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test? Acta Oncol. 2015;54(1):67–72. doi:10.3109/0284186X.2014.958531.

    Article  CAS  PubMed  Google Scholar 

  14. Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307–14. doi:10.1007/s00259-010-1539-5.

    Article  PubMed  Google Scholar 

  15. Wohrer S, Jaeger U, Kletter K, et al. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2006;17(5):780–4. doi:10.1093/annonc/mdl014.

    Article  CAS  Google Scholar 

  16. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683–90. doi:10.2967/jnumed.112.110890.

    Article  CAS  PubMed  Google Scholar 

  17. Bhargava P, Zhuang H, Kumar R, et al. Iatrogenic artifacts on whole-body F-18 FDG PET imaging. Clin Nucl Med. 2004;29(7):429–39.

    Article  PubMed  Google Scholar 

  18. Ulaner G, Lyall A. Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT. Radiographics. 2013;33:1817–34.

    Article  PubMed  Google Scholar 

  19. Sarji A. Physiological uptake in FDG PET simulating disease. doi:10.2349/biij.2.4.e59. Available on line http://www.biij.org/2006/4/e59.

  20. Mohei M, Abouzied MD, Elpida S, et al. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol. 2005;33:145–55.

    Google Scholar 

  21. Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95–9.

    Article  CAS  PubMed  Google Scholar 

  22. Oh JR, Song HC, Chong A, Ha JM, Jeong SY, Min JJ, Bom HS. Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin. AJR Am J Roentgenol. 2010;195:1404–10.

    Article  PubMed  Google Scholar 

  23. Sugawara Y, Fisher SJ, Zasadny KR, et al. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16(1):173–80.

    CAS  PubMed  Google Scholar 

  24. Sugawara Y, Zasadny KR, Kison PV, et al. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med. 1999;40(9):1456–62.

    CAS  PubMed  Google Scholar 

  25. Jerushalmi J, Frenkel A, Bar-Shalom R, et al. Physiologic thymic uptake of 18F-FDG in children and young adults: a PET/CT evaluation of incidence, patterns, and relationship to treatment. J Nucl Med. 2009;50(6):849–53.

    Article  PubMed  Google Scholar 

  26. Goethals I, Hoste P, De Vriendt C, et al. Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(3):462–7.

    Article  PubMed  Google Scholar 

  27. Kirsch J, Arrossi AV, Yoon JK, et al. FDG positron emission tomography/computerized tomography features of bleomycin-induced pneumonitis. J Thorac Imaging. 2006;21(3):228–30.

    Article  PubMed  Google Scholar 

  28. Buchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin’s disease: a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica. 2007;92(11):e120–1.

    Article  CAS  PubMed  Google Scholar 

  29. de Prost N, Tucci MR, Melo MF. Assessment of lung inflammation with 18F-FDG PET during acute lung injury. AJR Am J Roentgenol. 2010;195(2):292–300.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Faria S, Lisbona R, Stem J, et al. Is post-treatment FDG-PET/CT useful in differentiating tumor from fibrosis after curative radiation therapy (RT) alone for lung cancer? Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S519–20.

    Article  Google Scholar 

  31. Guerrero T, Johnson V, Hart J, et al. Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys. 2007;68(4):1030–5.

    Article  CAS  PubMed  Google Scholar 

  32. Hofman MS, Smeeton NC, Rankin SC, et al. Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging. J Nucl Med. 2009;50:1594–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, ASO Santa Croce e Carle, Cuneo, Italy

    Alberto Biggi MD

Authors
  1. Alberto Biggi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Biggi MD .

Editor information

Editors and Affiliations

  1. Research, Innovation and Statistics, A. Lacassagne Cancer Center, Nice, France

    Andrea Gallamini

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Biggi, A. (2016). PET Scan Reporting in Clinical Practice. In: Gallamini, A. (eds) PET Scan in Hodgkin Lymphoma. Springer, Cham. https://doi.org/10.1007/978-3-319-31797-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31797-7_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-31795-3

  • Online ISBN: 978-3-319-31797-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation